Healthcare / Drug Manufacturers - Specialty & GenericBSE
$46.56
+3.25 (+7.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-1.3B · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$25.5B
P/E
26.0x
↑EV/EBITDA
15.8x
↑ROE
7.6%
↑Gross Margin
37.8%
↓Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+8.5%
FCF CAGR
—
FCF margin
-7.1%
FCF / Net income
-1.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.06B · net income $948.8M · FCF $-1.28B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.06B | $18.06B | $18.12B | $16.82B | $14.14B |
| Net Income | $948.8M | $948.8M | $1.18B | $961.6M | $386.8M |
| EBITDA | $1.73B | $1.73B | $1.92B | $1.73B | $856.7M |
| EPS | 1.73 | 1.73 | 2.20 | 1.88 | 0.77 |
| Gross Margin | 37.8% | 37.8% | 36.0% | 35.6% | 31.4% |
| Operating Margin | 4.9% | 4.9% | 8.0% | 7.4% | 3.6% |
| Net Margin | 5.3% | 5.3% | 6.5% | 5.7% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.09 | 0.03 | 0.03 |
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.28B | $-1.28B | $-1.82B | $-79.6M | $-1.37B |
| Returns | |||||
| ROE | 7.6% | 7.6% | 10.2% | 11.3% | 5.1% |
| Valuation | |||||
| P/E | 26.01 | 26.01 | 22.40 | 25.53 | 35.10 |
| EV/EBITDA | 15.80 | 15.80 | 14.14 | 14.29 | 15.89 |
| P/B | 2.05 | 2.05 | 2.29 | 2.90 | 1.80 |
| Growth & Yield | |||||
| Revenue Growth | -0.3% | -0.3% | 7.7% | 19.0% | — |
| EPS Growth | -21.4% | -21.4% | 17.0% | 144.2% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
33.7%
EPS terminal req.
$4.13
Spread vs growth
-55.0%
5Y implied EPS CAGR
23.6%
EPS terminal req.
$5.00
Spread vs growth
-45.0%
10Y implied EPS CAGR
16.6%
EPS terminal req.
$8.05
Spread vs growth
-38.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.5%
Start / end P/E
30.3x → 26.9x
EPS bridge
2.20 → 1.73
Residual
+2.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.